Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:ABVX 20 November 2025 - 7 January 2026

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

Abivax shares jumped about 10% to $126 in early U.S. premarket trading after reports of renewed takeover speculation involving Eli Lilly and confirmation of Abivax’s addition to the Nasdaq Biotechnology Index. French media said Lilly representatives met with France’s Treasury about a possible acquisition, though Reuters could not confirm the meeting. Both companies declined to comment on the rumors.
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

Abivax shares fell about 5% in U.S. and Paris trading after reporting a nine-month net loss of €254.1 million, up from €136.9 million a year earlier. Cash and cash equivalents stood at €589.7 million as of September 30, expected to fund operations into Q4 2027. Investors weighed widening losses against a strong cash position and ongoing takeover speculation.
16 December 2025
···
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax shares surged 8% to $121.94 Thursday afternoon on heavy volume after fresh takeover rumors involving AstraZeneca. The French biotech’s stock is up about 1,450% year-to-date, fueled by strong Phase 3 ulcerative colitis data and M&A speculation. No deal has been confirmed by either company. Intraday volume reached 3.75 million ADSs, far above recent averages.
20 November 2025
··

Stock Market Today

  • Thomson Reuters (TRI) Upgraded to Buy on Rising Earnings Estimates
    April 9, 2026, 2:13 PM EDT. Thomson Reuters (TRI) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, a key factor influencing stock price movements. The Zacks rating, based solely on changes in earnings potential, signals an improved business outlook. This upgrade reflects growing confidence among institutional investors, who adjust share valuations based on earnings revisions, leading to potential stock price gains. The company is expected to earn $4.40 per share for the fiscal year ending December 2026, in line with last year. This upgrade highlights the importance of tracking earnings estimate revisions as a strategy for investment decisions in the near term.

Latest article

Dow Jones Today: Industrial Average Climbs as Oil Retreats, but Inflation Risk Keeps Wall Street Wary

Dow Jones Today: Industrial Average Climbs as Oil Retreats, but Inflation Risk Keeps Wall Street Wary

9 April 2026
The Dow Jones rose 247.66 points to 48,155.97 by midday Thursday, following a surge linked to signs of Middle East de-escalation and Israeli plans for peace talks with Lebanon. Oil prices fell over $4 a barrel after Netanyahu’s remarks, but remain 40% above pre-conflict levels. Amazon climbed 4.3% on strong AI revenue. Traders now see only a 30% chance of a Fed rate cut by year-end, down from 56%.
US Stock Market Today: Wall Street Rises Again, but Oil and Fed Fears Keep the Rally on Edge

US Stock Market Today: Wall Street Rises Again, but Oil and Fed Fears Keep the Rally on Edge

9 April 2026
The Dow rose 337 points, or 0.7%, by 1 p.m. Thursday as oil prices retreated after Israel announced direct talks with Lebanon and hopes for a U.S.-Iran ceasefire steadied markets. Amazon shares climbed on news its AWS AI services topped $15 billion in annualized revenue. The Fed signaled possible rate hikes if inflation persists. Oil shipments through the Strait of Hormuz remained sharply reduced.
Amazon Stock Rises After Andy Jassy Reveals AWS AI Revenue, Defends $200 Billion Spend

Amazon Stock Rises After Andy Jassy Reveals AWS AI Revenue, Defends $200 Billion Spend

9 April 2026
Amazon shares rose 5% Thursday after CEO Andy Jassy revealed AWS’s AI services are generating over $15 billion annually and its chip business more than $20 billion. Jassy said much of AWS’s $200 billion in planned 2026 spending is backed by customer commitments, including a $100 billion OpenAI deal. He also highlighted deep job cuts and a push for smaller teams. Amazon now operates over 1 million robots and plans to launch its Leo satellite network in mid-2026.
Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal

Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal

9 April 2026
Unilever said Thursday it will acquire U.S. greens-supplement brand Grüns for an undisclosed sum, with the deal expected to close later this year pending approvals. Grüns was valued at about $500 million in a 2025 Series B round, according to Reuters. The purchase follows Unilever’s recent agreement to combine its food business with McCormick.
Lumentum Stock Nears $960 After JPMorgan, Mizuho Raise Targets on Nvidia AI Optics Demand

Lumentum Stock Nears $960 After JPMorgan, Mizuho Raise Targets on Nvidia AI Optics Demand

9 April 2026
Lumentum shares climbed Thursday after JPMorgan raised its price target to $950, following Mizuho’s hike to $930. The moves come after Nvidia agreed last month to invest $2 billion in Lumentum and make multibillion-dollar purchase commitments. Lumentum reported February quarter revenue of $665.5 million, up 65.5% year-over-year. An SEC filing showed Lumentum will swap 5.7 million shares for $474.6 million in convertible notes.
Go toTop